Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Diabetic Macular Edema.

NCT04782115 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.

NCT NCT04782115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04782115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Diabetic Macular Edema.
Lead sponsor
RemeGen Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 17, 2021
Completion date
July 31, 2023
Enrollment
156 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema